Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | The challenges of implementing gene therapies for hemophilia in clinical practice

Michiel Coppens • 10 Jun 2023
EHA 2023
Hemophilia Non-Malignant

Michiel Coppens, MD, PhD, Amsterdam UMC, Amsterdam, The Netherlands, comments on the challenges of implementing gene therapies for hemophilia into clinical practice, highlighting economic challenges and the possibility of inequity in patient access. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Grant/research support: Anthos, Bayer, CSL Behring/UniQure, Novo Nordisk, Roche
Lecturing/consultancy: Alexion, CSL Behring, Daiichi Sankyo, Sobi, Viatris
Member EAHAD Gene Therapy working group, ERN-EuroBloodNet

More from Michiel Coppens

1:57
AAV gene therapies for hemophilia A and B
Michiel Coppens • 10 Jun 2023
1:18
Goals and work of the EAHAD gene therapy working group
Michiel Coppens • 10 Jun 2023
1:17
The current standard of care in hemophilia and unmet needs in this space
Michiel Coppens • 10 Jun 2023

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals